Literature DB >> 15292364

Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.

A Jain1, N S Fedarko, M T Collins, R Gelman, M A Ankrom, M Tayback, L W Fisher.   

Abstract

Matrix extracellular phosphoglycoprotein (MEPE), a member of the Small Integrin Binding Ligand N-linked Glycoprotein (SIBLING) family, is primarily expressed in normal bone and has been proposed as a phosphaturic factor because of high expression and secretion in oncogenic hypophosphatemic osteomalacia tumors. In order to begin to address the role of MEPE in normal human physiology, we developed a competitive ELISA to measure serum levels of MEPE. The ELISA was used to characterize the distribution pattern in a population consisting of 114 normal adult subjects. The mean value of MEPE was 476 +/- 247 ng/ml and levels decreased significantly with increasing age. MEPE levels were also significantly correlated with serum phosphorus and parathyroid hormone (PTH). In addition, MEPE levels correlated significantly with measures of bone mineral density in the femoral neck and total hip in a subset of 50 elderly subjects. The results are consistent with MEPE being involved in phosphate and bone metabolism in a normal population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292364     DOI: 10.1210/jc.2003-032031

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Novel mechanisms in the regulation of phosphorus homeostasis.

Authors:  Theresa Berndt; Rajiv Kumar
Journal:  Physiology (Bethesda)       Date:  2009-02

Review 2.  Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse.

Authors:  Qing Xiong; Yan Jiao; Karen A Hasty; S Terry Canale; John M Stuart; Wesley G Beamer; Hong-Wen Deng; David Baylink; Weikuan Gu
Journal:  Genomics       Date:  2009-01-14       Impact factor: 5.736

3.  Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

Authors:  Doron Bresler; Jan Bruder; Klaus Mohnike; William D Fraser; Peter S N Rowe
Journal:  J Endocrinol       Date:  2004-12       Impact factor: 4.286

Review 4.  The osteocyte: an endocrine cell ... and more.

Authors:  Sarah L Dallas; Matthew Prideaux; Lynda F Bonewald
Journal:  Endocr Rev       Date:  2013-04-23       Impact factor: 19.871

5.  Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.

Authors:  Shiguang Liu; Peter S N Rowe; Luke Vierthaler; Jianping Zhou; L Darryl Quarles
Journal:  J Endocrinol       Date:  2007-01       Impact factor: 4.286

6.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

Review 7.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

8.  Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.

Authors:  Aline Martin; Valentin David; Jennifer S Laurence; Patricia M Schwarz; Eileen M Lafer; Anne-Marie Hedge; Peter S N Rowe
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

Review 9.  The wrickkened pathways of FGF23, MEPE and PHEX.

Authors:  Peter S N Rowe
Journal:  Crit Rev Oral Biol Med       Date:  2004-09-01

10.  Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.

Authors:  William H Hoffman; Alka Jain; Harold Chen; Neal S Fedarko
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.